Clinical Trial

ULTRA-HFIB-Redo: Ultrasound-based Renal Sympathetic Denervation vs Control in Redo Ablation Patients

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This is a Prospective, controlled, single-blind, randomized (2:1, Intervention:Control) clinical trial. The purpose of the study is to determine the role of adjunctive renal sympathetic denervation in the prevention of Atrial Fibrillation (AF) recurrence in patients with hypertension scheduled for a redo AF ablation procedure for paroxysmal or persistent AF. Patients will be randomized to either i) AF ablation (Control) or ii) AF ablation + renal sympathetic denervation (Intervention).
Protocol Amendment History 2 changes
critical Enrollment closed, study ongoing 2026-07-31
notable Enrollment reduced: 250 -> 143 participants 2026-07-31
Trial Details
NCT Number NCT05988411
Lead Sponsor Vivek Reddy
Conditions Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
Enrollment 143 participants
Start Date 2023-12-07
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-30